Abstract:Abstract The MDM2 oncogene is amplified and/or overexpressed in many human cancers, including breast cancer, and it has been suggested as a molecular target for treating human cancers. MDM2 is a major negative regulator of tumor suppressor p53. Most MDM2 inhibitors under development are targeting the MDM2-p53 binding, and have little or no effects on cancers without functional p53, such as advanced breast cancer. Therefore, new strategies to target MDM2 are desirable. The present study was designed to develop a new class of MDM2 inhibitors that exert anti-breast cancer activity, regardless of p53 status in the cancers. The selective MDM2 inhibitors were discovered by a computational structure-based screening, yielding a lead compound, termed JapA. Fluorescence polarization (FP)-based binding assay and cellular thermal shift assay were performed to determine the binding between MDM2 and JapA. Its cytotoxicity was initially evaluated in breast cancer cell lines (MCF-7, MCF-7/p53−/−, MDA-MB-231, and MDA-MB-468) and normal human breast cells (MCF-10A). Its anti-breast cancer activities were further assessed in in vitro and in vivo MCF-7 and MDA-MB-231 models. The molecular mechanisms for its targeting effects on MDM2 were elucidated in various cell models in vitro and in vivo. We further found that JapA selectively inhibited breast cancer cell growth, decreased cell proliferation, and induced G2/M phase arrest and apoptosis in breast cancer cells through an MDM2-dependent mechanism, regardless of p53 status. In MCF-7 and MDA-MB-231 xenograft models, JapA inhibited MDM2 and suppressed tumor growth and lung metastasis in a dose-dependent manner, without host toxicity. Furthermore, JapA directly bound to MDM2 protein and reduced MDM2 levels in cancer cells in vitro and in vivo by promoting MDM2 protein degradation and inhibiting MDM2 transcription, which is distinct from the existing MDM2 inhibitors. In conclusion, JapA represents a new class of MDM2 inhibitor that exerts its anticancer activity through directly down-regulating MDM2, and might be developed as a novel cancer therapeutic agent. (Supported by the NIH R01 CA112029, R01 CA121211, and R01 CA186662) Citation Format: Jiang-Jiang Qin, Wei Wang, Sukesh Voruganti, Ruiwen Zhang. A novel MDM2 inhibitor suppresses breast cancer growth and metastasis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2433. doi:10.1158/1538-7445.AM2015-2433

Platycodin D, a Metabolite of Platycodin Grandiflorum, Inhibits Highly Metastatic MDA-MB-231 Breast Cancer Growth in Vitro and in Vivo by Targeting the MDM2 Oncogene.

Inhibitory Effect of Platycodin D on Human Colonic Cancer SW620 Cell Proliferation

Platycodin D Inhibits Tumor Growth by Antiangiogenic Activity Via Blocking VEGFR2-mediated Signaling Pathway

Platycodin-D exerts its anti-cancer effect by promoting c-Myc protein ubiquitination and degradation in gastric cancer

Platycodin D Inhibits Glioblastoma Cell Proliferation, Migration, and Invasion by Regulating DEPDC1B-mediated Epithelial-to-mesenchymal Transition.

Platycodin D induces proliferation inhibition and mitochondrial apoptosis in diffuse large B-cell lymphoma

Platycodin D Suppresses Proliferation, Migration, and Invasion of Human Glioblastoma Cells Through Regulation of Skp2

Platycodin D Inhibits Proliferation, Migration and Induces Chemosensitization Through Inactivation of the NF‐κB and JAK2/STAT3 Pathways in Multiple Myeloma Cells

Platycodin D reduces PD‐L1 levels by inhibiting LXR‐β activity and combines with nintedanib to enhance the tumor‐killing effect of T cells

Effects of Platycodin D on Apoptosis, Migration, Invasion and Cell Cycle Arrest of Gallbladder Cancer Cells.

Platycodin D induces apoptosis via regulating MAPK pathway and promotes autophagy in colon cancer cell

Investigation of the Inhibitory Effect of Platycodin D in Human Transitional Cell Carcinoma Cell Line 5637.

Platycodin D induces apoptotic cell death through PI3K/AKT and MAPK/ERK pathways and synergizes with venetoclax in acute myeloid leukemia

Platycodin D Triggers Autophagy Through Activation of Extracellular Signal-Regulated Kinase in Hepatocellular Carcinoma HepG2 Cells.

Platycodin D, a triterpenoid saponin from Platycodon grandiflorum, suppresses the growth and invasion of human oral squamous cell carcinoma cells via the NF‐κB pathway

Platycodin-D Induced Autophagy in Non-Small Cell Lung Cancer Cells via PI3K/Akt/mTOR and MAPK Signaling Pathways

Reveal the Pharmacodynamic Substances and Mechanism of an Edible Medicinal Plant Platycodonis Radix Inhibits Tumor

Targeting the ROS/PI3K/AKT/HIF‐1α/HK2 Axis of Breast Cancer Cells: Combined Administration of Polydatin and 2‐Deoxy‐d‐glucose

Abstract 2433: A Novel MDM2 Inhibitor Suppresses Breast Cancer Growth and Metastasis

Deapioplatycodin D promotes cell senescence induced by P21 through the mediation of incomplete mitophagy via BNIP3L

Dendropanax morbiferus H. Lév. Leaf Extract Inhibits the Proliferation of MDA-MB-231 Breast Cancer Cells and Induces Apoptosis via the MAPK Pathway In Vitro and In Vivo